MX2021007833A - Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer. - Google Patents

Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer.

Info

Publication number
MX2021007833A
MX2021007833A MX2021007833A MX2021007833A MX2021007833A MX 2021007833 A MX2021007833 A MX 2021007833A MX 2021007833 A MX2021007833 A MX 2021007833A MX 2021007833 A MX2021007833 A MX 2021007833A MX 2021007833 A MX2021007833 A MX 2021007833A
Authority
MX
Mexico
Prior art keywords
mat2a
methods
aza
treating cancer
inhibitors
Prior art date
Application number
MX2021007833A
Other languages
English (en)
Inventor
Zenon D Konteatis
Jeremy M Travins
Samuel K Reznik
Li Mingzong
Sui Zhihua
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of MX2021007833A publication Critical patent/MX2021007833A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente descripción proporciona compuestos de acuerdo con la Fórmula I, Fórmula II, y sus sales, tautómeros y/o isotopólogos farmacéuticamente aceptables como se describe en la descripción. Los compuestos son inhibidores de la isoforma 2A de la metionina adenosiltransferasa (MAT2A). También se proporcionan composiciones farmacéuticas y métodos para usar los compuestos para tratar cánceres, que incluyen algunos cánceres en los que se elimina el gen que codifica la metiltioadenosina fosforilasa (MTAP).
MX2021007833A 2018-12-27 2019-12-27 Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer. MX2021007833A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785574P 2018-12-27 2018-12-27
PCT/US2019/068653 WO2020139992A1 (en) 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (1)

Publication Number Publication Date
MX2021007833A true MX2021007833A (es) 2021-10-26

Family

ID=69400626

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007833A MX2021007833A (es) 2018-12-27 2019-12-27 Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer.

Country Status (21)

Country Link
US (1) US20220098203A1 (es)
EP (1) EP3902804A1 (es)
JP (1) JP2022516882A (es)
KR (1) KR20220050832A (es)
CN (1) CN113474347A (es)
AR (1) AR115296A1 (es)
AU (1) AU2019414446A1 (es)
BR (1) BR112021012599A2 (es)
CA (1) CA3124678A1 (es)
CL (1) CL2021001722A1 (es)
CO (1) CO2021009882A2 (es)
CR (1) CR20210409A (es)
EA (1) EA202191800A1 (es)
IL (1) IL284324A (es)
JO (1) JOP20210171A1 (es)
MA (1) MA54609A (es)
MX (1) MX2021007833A (es)
PE (1) PE20212303A1 (es)
SG (1) SG11202106627WA (es)
TW (1) TW202039489A (es)
WO (1) WO2020139992A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105469YA (en) 2018-12-10 2021-06-29 Ideaya Biosciences Inc 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2021219731A2 (en) * 2020-04-28 2021-11-04 Iomx Therapeutics Ag Bicyclic kinase inhibitors and uses thereof
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
TW202227443A (zh) * 2020-12-31 2022-07-16 中國商江蘇先聲藥業有限公司 三環類化合物及用途
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2023116696A1 (zh) * 2021-12-21 2023-06-29 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
WO2023143356A1 (zh) * 2022-01-26 2023-08-03 勤浩医药（苏州）有限公司 用于治疗mtap缺失型癌症的甲硫氨酸腺苷转移酶2a抑制剂
TW202342024A (zh) * 2022-03-11 2023-11-01 大陸商賽諾哈勃藥業（成都）有限公司 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用
GB202204913D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd antiviral therapy
WO2024080788A1 (ko) 2022-10-13 2024-04-18 한미약품 주식회사 신규한 트리사이클 유도체 화합물 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
AU769989B2 (en) * 1998-10-23 2004-02-12 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
IL149100A0 (en) * 1999-10-21 2002-11-10 Hoffmann La Roche Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7129351B2 (en) * 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
KR100864393B1 (ko) * 2003-04-10 2008-10-20 에프. 호프만-라 로슈 아게 피리미도 화합물
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CN104418860B (zh) * 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
CA3034705C (en) * 2016-08-31 2021-08-03 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CN109384790B (zh) * 2017-08-08 2022-05-10 药捷安康(南京)科技股份有限公司 成纤维细胞生长因子受体抑制剂及其用途
PL3774805T3 (pl) * 2018-03-30 2024-05-06 Les Laboratoires Servier Heterobicykliczne inhibitory mat2a i sposoby przydatne do leczenia nowotworu

Also Published As

Publication number Publication date
IL284324A (en) 2021-08-31
KR20220050832A (ko) 2022-04-25
JP2022516882A (ja) 2022-03-03
EA202191800A1 (ru) 2021-09-13
BR112021012599A2 (pt) 2021-09-08
MA54609A (fr) 2022-04-06
AU2019414446A1 (en) 2021-07-15
EP3902804A1 (en) 2021-11-03
AR115296A1 (es) 2020-12-16
SG11202106627WA (en) 2021-07-29
CA3124678A1 (en) 2020-07-02
PE20212303A1 (es) 2021-12-10
CO2021009882A2 (es) 2021-10-29
US20220098203A1 (en) 2022-03-31
JOP20210171A1 (ar) 2023-01-30
WO2020139992A1 (en) 2020-07-02
TW202039489A (zh) 2020-11-01
CN113474347A (zh) 2021-10-01
CR20210409A (es) 2022-01-24
CL2021001722A1 (es) 2022-02-18

Similar Documents

Publication Publication Date Title
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
ZA202104423B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
JOP20210171A1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
PH12020551507A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12021551274A1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
PH12021550995A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
MX2022014648A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
JOP20200342A1 (ar) مشتقات بيرازين مدمجة كمثبطات a2a/a2b
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy